Home > Publications & Media > Principal Investigators
Publications & Media

Publications by CIDRI-Africa Principal Investigators

Frank Brombacher

Hurdayal R, Ndlovu HH, Revaz-Breton M, Parihar SP, Nono JK, Govender M, Brombacher F. IL-4-producing B cells regulate T helper cell dichotomy in type 1- and type 2-controlled diseases. Proc Natl Acad Sci USA. (2017) 114: E8430-E8439.

Hoving JC, Cutler AJ, Leeto M, Horsnell WG, Dewals BG, Nieuwenhuizen NE, Brombacher F. . Interleukin 13-mediated colitis in the absence of IL-4Ra signalling.  Gut. (2017) 66: 2037-2039.

Parihar SP, Ozturk M, Marakalala MJ, Loots DT, Hurdayal R, Beukes D, Van Reenen M, Zak DE, Mbandi SK, Darboe F, Penn-Nicholson A, Hanekom WA, Leitges M, Scriba TJ, Guler R, Brombacher F. . Protein kinase C-delta (PKCd), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice. Mucosal Immunol. (2017) Aug 23. doi: 10.1038/mi.2017.68.

 

Gary Maartens

Griesel R, Stewart A, van der Plas H, Sikhondze W, Rangaka MX, Nicol MP, Kengne AP, Mendelson M, Maartens G. Optimizing tuberculosis diagnosis in Human Immunodeficiency Virus–infected inpatients meeting the criteria of Seriously Ill in the World Health Organization algorithm. Clinical Infectious Diseases. (in press) https://doi.org/10.1093/cid/cix988

Dheda K, Barry CE, Maartens G. Tuberculosis. The Lancet. (2016) 387(10024):1211–26.

Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, Wilkinson KA, Goliath R, Mathee S, Goemaere E, Maartens G. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. The Lancet. (2014) 384(9944):682–90.

 

Helen McIlleron

Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H. Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children. Journal of Acquired Immune Deficiency Syndromes (1999). (2016) 73(2):161–8.

McIlleron H, Hundt H, Smythe W, Bekker A, Winckler J, van der Laan L, Smith P, Zar HJ, Hesseling AC, Maartens G, Wiesner L, van Rie A. Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes. The International Journal of Tuberculosis and Lung Disease. (2016) 20(7):915–9.­

Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrobial Agents and Chemotherapy. (2015) 59(1):38–45.

 

Thomas Scriba

Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK-K, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ, Hatherill M. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. The Lancet Respiratory Medicine. (2018) 6(4):287–98.
 
Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, Nemes E, Darboe F, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Johnson JL, Boom WH, Hatherill M, Valvo J, De Groote MA, Ochsner UA, Aderem A, Hanekom WA, Zak DE, other members of the ACS cohort study team. Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLOS Pathogens. (2017) 13(11):e1006687.
 
Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. The Lancet. (2016) 387(10035):2312–22.

 

Carolyn Williamson

Selhorst P, Masson L, Ismail SD, Samsunder N, Garrett N, Mansoor LE, Abdool Karim Q, Abdool Karim SS, Passmore J-AS, Williamson C. Cervicovaginal inflammation facilitates acquisition of less infectious HIV variants. Clinical Infectious Diseases. (2017) 64(1):79–82.

Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR, Gao H, Greene KM, Tang H, Bandawe GP, Marais JC, Diphoko TE, Hraber P, Tumba N, Moore PL, Gray GE, Kublin J, McElrath MJ, Vermeulen M, Middelkoop K, Bekker L-G, Hoelscher M, Maboko L, Makhema J, Robb ML, Abdool Karim S, Abdool Karim Q, Kim JH, Hahn BH, Gao F, Swanstrom R, Morris L, Montefiori DC, Williamson C. Features of recently transmitted HIV-1 clade C viruses that impact antibody recognition: implications for active and passive immunization. PLOS Pathogens. (2016) 12(7):e1005742.

Bhiman JN, Anthony C, Doria-Rose NA, Karimanzira O, Schramm CA, Khoza T, Kitchin D, Botha G, Gorman J, Garrett NJ, Abdool Karim SS, Shapiro L, Williamson C, Kwong PD, Mascola JR, Morris L, Moore PL. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nature Medicine. (2015) 21(11):1332–6.

TOP